



RS Global

ISSN 2413-1032



WORLD SCIENCE

Multidisciplinary Scientific Edition

WORLD SCIENCE

№ 1(29)
Vol.3, January 2018

Copies may be made only from legally acquired originals.

A single copy of one article per issue may be downloaded for personal use (non-commercial research or private study). Downloading or printing multiple copies is not permitted. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter. Permission of the Publisher is required for all other derivative works, including compilations and translations. Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means without prior written permission of the Publisher.

Publisher –
RS Global Sp. z O.O.,

Scientific Educational Center
Warsaw, Poland

Numer KRS: 0000672864
REGON: 367026200
NIP: 5213776394

Publisher Office's address:

Dolna 17,
Warsaw, Poland,
00-773

Website: <https://ws-conference.com/>

E-mail: rsglobal.poland@gmail.com

Tel: +4(857) 898 55 10

The authors are fully responsible for the facts mentioned in the articles. The opinions of the authors may not always coincide with the editorial boards point of view and impose no obligations on it.

CHIEF EDITOR

Ramachandran Nithya Professor in Finance and Marketing, Oman

EDITORIAL BOARD:

Nobanee Haitham Associate Professor of Finance, United Arab Emirates

Temirbekova Sulukhan Dr. Sc. of Biology, Professor, Russian Federation

Almazari Ahmad Professor in Financial Management, Saudi Arabia

Kuzmenkov Sergey Professor at the Department of Physics and Didactics of Physics, Candidate of Physico-mathematical Sciences, Doctor of Pedagogic Sciences

Lina Anastassova Full Professor in Marketing, Bulgaria

Safarov Mahmatali Doctor Technical Science, Professor Academician Academia Science Republic of Tajikistan

Mikiashvili Nino Professor in Econometrics and Macroeconomics, Georgia

Omarova Vera Professor, Ph.D., Kazakhstan

Alkhawaldeh Abdullah Professor in Financial Philosophy, Hashemite University, Jordan

Koziar Mykola Head of the Department, Doctor of Pedagogical Sciences, Ukraine

Mendebaev Toktamys Doctor of Technical Sciences, Professor, Kazakhstan

Tatarintseva Nina Professor, Russia

Yakovenko Nataliya Professor, Doctor of Geography, Shuya

Sidorovich Marina Candidate of Biological Sciences, Doctor of Pedagogical Sciences, Full Professor

Mazbayev Ordenbek Doctor of Geographical Sciences, Professor of Tourism, Kazakhstan

Polyakova Victoria Candidate of Pedagogical Sciences, Russia

Sentyabrev Nikolay Professor, Doctor of Sciences, Russia

Issakova Sabira Professor, Doctor of Philology,

Kolesnikova Galina Professor, Russia

Ustenova Gulbaram Director of Education Department of the Pharmacy, Doctor of Pharmaceutical Science, Kazakhstan

Utebaliyeva Gulnara Doctor of Philological Science, Kazakhstan

Harlamova Julia Professor, Russia

Uzilevsky Gennady Dr. of Science, Ph.D., Russian Federation

Kalinina Irina Professor of Chair of Medicobiological Bases of Physical Culture and Sport, Dr. Sci.Biol., Russia

Crohmal Natalia Professor, Ph.D. in Philosophy, National Pedagogical Dragomanov University, Ukraine

Imangazinov Sagit Director, Ph.D, Kazakhstan

Chorny Oleksii D.Sc. (Eng.), Professor, Kremenchuk

Dukhanina Irina Professor of Finance and Investment Chair, Doctor of Sciences, Russian Federation

Pilipenko Oleg Head of Machine Design Fundamentals Department, Doctor of Technical Sciences, Ukraine

Orehowskyi Wadym Head of the Department of Social and Human Sciences, Economics and Law, Doctor of Historical Sciences, Ukraine

Nyyazbekova Kulanda Candidate of pedagogical sciences, Kazakhstan

Cheshmedzhieva Margarita Public Law and Public Management Department, Bulgaria

Peshcherov Georgy Professor, Russia

Svetlana Peneva MD, dental prosthetics, Medical University - Varna, Bulgaria

Mustafin Muafik Professor, Doctor of Veterinary Science

Ovsyanik Olga Professor, Doctor of Psychological Science, Russian Federation

Rossikhin Vasiliy Full dr., Doctor of Legal Sciences, National Law University named after Yaroslav the Wise, Ukraine

CONTENTS

MEDICINE

- Antonenko M., Zelinskaya N., Znachkova O., Revych V., Syroyishko M.*
THE BASICS APPROACH TO BONE ANTIGEN AND LOCAL IMMUNITY
OF ORAL CAVITY AT THE STAGE OF PROSTHETIC SUPPORT OF THE
COMPREHENSIVE TREATMENT OF THE GENERALIZED PERIODONTITIS..... 4
- Kirkilevsky S. I., Mashukov A. A., Tkachenko O. I., Luk`yanchuk O. V.,
Maximovsky V. E., Bilenko A. A., Merlich S. V., Ratsiborsky D. V., Boychenko A. I.*
COMPARISON OF SURVIVAL RATES MADE BY THE 6TH
AND 7TH EDITIONS OF TNM CLASSIFICATION IN STOMACH CANCER PATIENTS..... 9
- Valeriy Zaporozhan, Olexandr Tkachenko, Andriy Rybin*
BIOMARKERS OF PLATINUM RESISTANCE IN SEROUS OVARIAN CANCER..... 17
- Zaporozhan V. M., Tkachenko O. I., Maksymovskiy V. Y., Mashukov A. O., Pyrogov V. V.*
OPTIMAL SURGICAL TREATMENT OF LOCALLY ADVANCED
GYNECOLOGICAL MALIGNANCIES..... 20
- Горошко О. М., Паламар А. О., Матущак М. Р., Василичук О. Я.,
Богдан Н. С., Драчук В. М., Ежнед М. А.*
РОЛЬ ВИЩОГО НАВЧАЛЬНОГО ЗАКЛАДУ
У СТАНОВЛЕННІ СПЕЦІАЛІСТА В ГАЛУЗІ ФАРМАЦІЇ..... 23
- Дадаян В. А.*
ОСОБЛИВОСТІ ПАТОГЕНЕЗУ ТА ПРОФІЛАКТИКИ ТРОАКАРНИХ ГРИЖ
ПІСЛЯ ЛАПАРОСКОПІЧНОЇ ХОЛЕЦИСТЕКТОМІЇ..... 26
- Жалдак П. І., Крупельницька І. Г.*
АДАПТАЦІЯ ЛЮДЕЙ ПОХИЛОГО ВІКУ ДО СУЧАСНИХ СОЦІАЛЬНИХ УМОВ..... 34
- Писклова Ю. В., Бучнева О. В.*
ОПЫТ ЛЕЧЕНИЯ ЭКССУДАТИВНЫХ ПЕРИКАРДИТОВ
С ИСПОЛЬЗОВАНИЕМ МИНИИНВАЗИВНЫХ ДОСТУПОВ..... 39
- Шамансуров Ш. Ш., Мутаиллоева Д. С.*
НЕРВНО - ПСИХИЧЕСКОЕ РАЗВИТИЕ ДЕТЕЙ
С РОДОВЫМИ ПОВРЕЖДЕНИЯМИ НЕРВНОЙ СИСТЕМЫ..... 42
- Цырук Е. В., Поволоцкая Е. Ю., Макиенко Н. В., Кротенко А. В.*
РЕАЛЬНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА:
МУЛЬТИМОРБИДНОСТЬ И ЛЕЧЕБНАЯ ТАКТИКА..... 45
- Savytskiy I. V., Kuzmenko I. A., Sarahan V. M., Yakymchuk N. V.*
REPRODUCTION OF DIABETES MELLITUS` TYPES IN AN EXPERIMENT..... 49
- Barseghyan H. A., Voskanyan A. A., Harutyunyan H. V.*
PECULIARITIES OF INTRA-ABDOMINAL AND ABDOMINAL PERFUSION PRESSURES IN
EPIDURALLY ANESTHETIZED PATIENTS WITH CHOLECYSTOPANCREATITIS..... 52

PHARMACY

- Мнушко З. Н., Пестун И. В.*
СОВРЕМЕННЫЕ ПОДХОДЫ К УПРАВЛЕНИЮ
ЗНАНИЯМИ СОТРУДНИКОВ ФАРМАЦЕВТИЧЕСКИХ ФИРМ..... 55

OPTIMAL SURGICAL TREATMENT OF LOCALLY ADVANCED GYNECOLOGICAL MALIGNANCIES

Zaporozhan V. M. MD, DSc, CEO,
 Tkachenko O. I., MD, DSc,
 Maksymovskiy V. Y., MD, PhD,
 Mashukov A. O., MD, PhD,
 Pyrogov V. V., MBBS

Ukraine, Odessa, Odessa National Medical University,
 Department of Surgery № 4 with a Course of Oncology

Abstract. The article presents our experience of advanced gynecological malignancies surgical treatment. We retrospectively analyzed 1215 cases of gynecological malignancies and selected 313 patients with locally advanced disease. All patients undergone surgical treatment in University Clinic of Odessa national medical university from 2006 till 2017. 32 HIPEC procedures were included in this study, 24 with cytoreduction. One-year survival was 88,6 % for cervical cancer, 85,2 % for ovarian cancer, 79,1 % for endometrial cancer. Five and ten year survival rate was 31 % and 14 % among ovarian cancer patients, 18 % and 9 % for ovarian cancer, 38 % and 18 % for endometrial cancer respectively. Cytoreduction with HIPEC were well tolerated with no perioperative mortality.

Keywords: Gynecological malignancy, HIPEC, cytoreduction, pelvic exenteration, urinary diversion.

Introduction. Development of more effective approaches in surgical treatment of malignant gynecological pelvic tumors remains an actual oncologic problem. Despite recent advances in early diagnosis many patients present with regionally advanced tumors or even metastatic spread [1]. Another problem is local recurrence in pelvic cavity of malignant tumors, like rectal, ovarian, uterine cancer [2,3]. Large pelvic masses lead to intestinal, ureteral obstruction, are frequently complicated by recurrent hemorrhage. Palliative systemic chemotherapy is contraindicated in such conditions. Obviously, more sophisticated methods of combined treatment need to be developed in order to improve oncological results, to alleviate the quality of life.

Objectives. To determine the efficacy and safety of complex surgical treatment for advanced and recurrent gynecological pelvic malignancies.

Materials and methods. We retrospectively analyzed 1215 cases of gynecological malignancies and selected 313 patients with locally advanced disease. All patients undergone treatment in University Clinic of Odessa national medical university from 2006 till 2017. Data about primary tumor localization is presented in Table 1.

Table 1. Primary tumor characteristics

Localization	Number of patients		FIGO III-IV		Recurrence after treatment	
	n	%	n	%	n	%
Cervical cancer	406	33,4	150	47,9	17	4,2
Endometrial cancer	389	32,0	72	23,0	9	2,3
Ovarian cancer	420	34,6	91	29,0	30	7,1
Overall	1215		313		56	

Preoperative investigations included clinical assessment, general laboratory tests, CT scans of abdominal, pelvic, chest cavities and retroperitoneum, cystoscopy, rigid sigmoidoscopy. Head CT was indicated if brain metastasis suspected. In selected cases PET CT was additionally needed.

Surgical treatment depended on disease stage, local spread. Despite differences among clinical cases, operative techniques shared some common features. Initially ureters were mobilized, held with tourniquets. Tumor mass was excised en block. In case of urinary bladder wall involvement, frozen specimens were obtained to assess resected margins. If rectum was involved, we performed low anterior or abdominopelvic resection.

In patients with good prognosis anterior, posterior or total pelvic exenteration was done with urinary bladder resection, psoas hitch and Boari flap ureteroneocystostomy. These also was

appropriate for selected cases without extensive urinary bladder infiltration, where 2/3 of volume could be preserved and no bladder neck lesion was seen.

Patients with intermediate prognosis and life expectancy less than 3 years, patients after pelvic radiation therapy required total pelvic exenteration with sigmoidostomy and ureterosigmoidostomy for urine derivation.

Briker ileal conduit urinary diversion after posterior, anterior and total pelvic exenteration was performed in patients with good and intermediate prognosis with life expectancy more than 3 years or after radiation therapy.

Since 2016 our clinic performs cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion for ovarian cancer with peritoneal involvement. 32 HIPEC procedures were included in this study, 24 with cytoreduction. Optimal cytoreduction precluded closed-abdomen HIPEC on Performer HT (Rand Biotech, Italy). The combination of cisplatin (100 mg/m²) and doxorubicin (25 mg/m²) in 4000 ml of carrier solution irrigated abdominal cavity with the flow rate 600-1200 ml/min. After the temperature reached 41-42 C the perfusion lasted 60-90 minutes (depending on cytoreduction volume).

Cytoreduction was performed in cases with malignant carcinomatosis involvement [4]. However, the optimal cytoreduction was contraindicated if extensive mesentery involvement, distant metastasis of irresectable lymphadenopathy were present. Bowel obstruction was also considered an absolute contraindication [5].

Results. A total of 313 patients were included in the study. The mean patient age was 48,3 ± 5 years (range, 34-70 years). 94 patients underwent modified radical hysterectomy, 86 - classical radical hysterectomy, 75 patients – Bochman hysterectomy, 58 – excision of recurrent tumor. Operative approaches included omentectomy (n=286, 91,4 %), extended pelvic lymphadenectomy (n=174, 55,6 %), urinary bladder resection (n=110, 35,1 %) with psoas hitch unilateral ureterocystoneostome (n=35, 11,2 %) or bilateral ureteroneocystostomy (n=24, 7,7 %). Anterior (n=15, 4,8 %) or abdominoperineal (n=3, 1,0 %) resection of the rectum was required in cases of direct bowel invasion. Anterior pelvic evisceration with Briker ileal conduit was performed in 16 patients (5,1 %) with advanced local tumor spread. 12 patients (3,8 %) underwent posterior pelvic exenteration and 3 (1,0 %) – total. Selective peritonectomy was done in 24 (7,7 %) cases.

Intraoperative and postoperative periods were complicated by wound infection (n=24, 7,7 %), bleeding (n=7, 2,2 %), ureteral anastomosis stricture (n=3, 1,0 %), vesical fistula (n=4, 1,3 %), hypogastric arteries injury (n=2, 0,6 %), intestinal anastomosis leakage (n=3, 1,0 %), pulmonary embolism (n=3, 1,0 %). Overall postoperative mortality was 12 cases due to major hemorrhage (n=6, 1,9 %), pulmonary embolism (n=3, 1,0 %), peritonitis (n=3, 1,0 %).

One-year survival was 88,6 % for cervical cancer, 85,2 % for ovarian cancer, 79,1 % for endometrial cancer. Five and ten year survival rate was 31 % and 14 % among ovarian cancer patients, 18 % and 9 % for ovarian cancer, 38 % and 18 % for endometrial cancer respectively.

There were no systemic complication in cytoreduction and HIPEC group, however 1 case of hemorrhage (4,1 %), 1 bowel perforation (4,1 %) occurred. No perioperative mortality was observed.

Discussion. Some principles were developed basing on our surgical experience of advanced gynecology oncology treatment. Adequate transabdominal incision is necessary. Good visualization of major vessels, ureters, obturator nerve may help to define tumor topographical relations and avoid inadvertent iatrogenic injuries. Affected ureters must be resected enough with frozen section of surgical margins to achieve radical excision. Ureters should be manipulated gently regarding their blood supply. Prior to extended lymphadenectomy it is essential to ligate internal hypogastric arteries and occlude internal hypogastric arteries temporarily in order to prevent major hemorrhage when accidentally tearing blood vessels.

Conclusions.

1. Extensive urinary tract lesion should not limit surgical approach in treatment of advanced pelvic malignancies.

2. Bowel reconstruction possibility depends on its tumor invasion. Taking into account complexity of surgical treatment it is more suitable to perform ostomy with further possible reconstruction.

3. Limited carcinomatosis is not a contraindication for surgery. Cytoreduction and HIPEC is an appropriate treatment option in selected cases, depending on peritoneal carcinomatosis index, tumor biological properties.

REFERENCES

1. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study / M. Deraco, C. R. Rossi et al. *Tumori*. 2001. Vol. 87, № 3. P. 120-126.
2. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? / A. Shido, S. Ohmura, K. Yamamoto et al. *World J. Surg.* 2000. Vol. 24. P. 507-511.
3. Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot / F. A. Zoetmulder, M. M. Kaag, J. H. Beijnen et al. *Eur J. Surg. Oncol.* 2000. Vol. 26, № 7. P. 663-668
4. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis / P. Shen, E. A. Levine, J. Hall et al. *Arch. Surg.* 2003. Vol. 138, № 1. P. 26-33.
5. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adducts formation in patients and ovarian cancer lines / P. J. M. van der Vaart, N. van der Vange, F. A. N. Zoetmulder et al. *Eur. J. Cancer.* 1998. Vol 34, № 1. P. 148-154.